Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277863 | 0.95 | IDO1 (0.41) | KDM4EPKMMAPTJAK2NOTCH1 | |
| SCHEMBL16213231 | 0.88 | KCNH2 (0.43) | — | |
| SCHEMBL14367721 | 0.80 | KCNH2 (0.42) | — | |
| SCHEMBL3271883 | 0.77 | KCNH2 (0.44) | NAMPT | |
| SCHEMBL14611171 | 0.76 | GPR119 (0.51) | GPR119 | |
| SCHEMBL3277869 | 0.76 | KCNH2 (0.36) | — | |
| SCHEMBL3272794 | 0.76 | LIMK2 (0.40) | JAK2JAK1BACE1GPR119 | |
| SCHEMBL16213215 | 0.75 | KCNH2 (0.46) | — | |
| SCHEMBL6584233 | 0.75 | KDM4E (0.51) | KDM4EPKMMAPTJAK2JAK1 | |
| SCHEMBL20379150 | 0.74 | KDM4E (0.50) | KDM4EPKMMAPTJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991992-B1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9540399-B2 | Quinolone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-10 | — | — | US | disclosed |
| EP-2991992-A1 | QUINOLONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060276-A1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-03 | — | — | US | disclosed |
| WO-2014178008-A1 | QUINOLONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060276-A1 | QUINOLONE DERIVATIVES | NQO2, QARS1, RECQL | KDM4E 2055/4885PKM 3911/4885MAPT 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.